JP2018538246A - Acc阻害剤およびその使用 - Google Patents
Acc阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2018538246A JP2018538246A JP2018521087A JP2018521087A JP2018538246A JP 2018538246 A JP2018538246 A JP 2018538246A JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018538246 A JP2018538246 A JP 2018538246A
- Authority
- JP
- Japan
- Prior art keywords
- grams
- membered
- ring
- independently selected
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(CN(c([s]c(*)c1*)c1C(N1[C@@](CCN2*)C2=O)=O)C1=O)c(cccc1)c1O* Chemical compound *C(CN(c([s]c(*)c1*)c1C(N1[C@@](CCN2*)C2=O)=O)C1=O)c(cccc1)c1O* 0.000 description 35
- VPGMTWPNGYFPQA-UHFFFAOYSA-N CCOC(c1c(N)[s]c(-[n]2nccn2)c1C)=O Chemical compound CCOC(c1c(N)[s]c(-[n]2nccn2)c1C)=O VPGMTWPNGYFPQA-UHFFFAOYSA-N 0.000 description 2
- GNRCSWVAFGZUEK-LBPRGKRZSA-N COCCO[C@@H](CO)c1cc(F)ccc1OC Chemical compound COCCO[C@@H](CO)c1cc(F)ccc1OC GNRCSWVAFGZUEK-LBPRGKRZSA-N 0.000 description 2
- VWQMPKWCTBZDMB-KNQAVFIVSA-N CC(C)C(N(CC1)C[C@@H]1N(C(c1c(N2C[C@@H](c(cc(cc3)F)c3OC)OCCO)[s]c(-[n]3nccn3)c1C)=O)C2=O)=O Chemical compound CC(C)C(N(CC1)C[C@@H]1N(C(c1c(N2C[C@@H](c(cc(cc3)F)c3OC)OCCO)[s]c(-[n]3nccn3)c1C)=O)C2=O)=O VWQMPKWCTBZDMB-KNQAVFIVSA-N 0.000 description 1
- WMTAQNQUDGWFEE-IAXKEJLGSA-N CC(C)N(CCCC1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCO)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CC(C)N(CCCC1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCO)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O WMTAQNQUDGWFEE-IAXKEJLGSA-N 0.000 description 1
- WMTAQNQUDGWFEE-IRLDBZIGSA-N CC(C)N(CCC[C@H]1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCO)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CC(C)N(CCC[C@H]1N(C(c2c(N3C[C@@H](c4cc(F)ccc4OC)OCCO)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O WMTAQNQUDGWFEE-IRLDBZIGSA-N 0.000 description 1
- QAQNBXREJHUVBY-YANBTOMASA-N CCN(CCC1N(C(c2c(N3C[C@@H](c(cc(cc4)F)c4OC)OC4CCOCC4)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O Chemical compound CCN(CCC1N(C(c2c(N3C[C@@H](c(cc(cc4)F)c4OC)OC4CCOCC4)[s]c(-[n]4nccn4)c2C)=O)C3=O)C1=O QAQNBXREJHUVBY-YANBTOMASA-N 0.000 description 1
- ORZPHNUYXKOTTR-UHFFFAOYSA-N CCOC(c1c(NC(NC(C2)CNC2=O)=O)[s]c(-[n]2nccn2)c1C)=O Chemical compound CCOC(c1c(NC(NC(C2)CNC2=O)=O)[s]c(-[n]2nccn2)c1C)=O ORZPHNUYXKOTTR-UHFFFAOYSA-N 0.000 description 1
- NCINFVNVWCDDAN-UHFFFAOYSA-N CCOC(c1c(NC(NC(CCN2)C2=O)=O)[s]c(-[n]2nccn2)c1C)=O Chemical compound CCOC(c1c(NC(NC(CCN2)C2=O)=O)[s]c(-[n]2nccn2)c1C)=O NCINFVNVWCDDAN-UHFFFAOYSA-N 0.000 description 1
- YYPGHMRGEZCKPT-MOOYVADDSA-N CCOCCO[C@@H](CN(c([s]c(-[n]1nccn1)c1C)c1C(N1C(C2)(C2CN2)C2=O)=O)C1=O)c(cc(cc1)F)c1OCc1ccccc1 Chemical compound CCOCCO[C@@H](CN(c([s]c(-[n]1nccn1)c1C)c1C(N1C(C2)(C2CN2)C2=O)=O)C1=O)c(cc(cc1)F)c1OCc1ccccc1 YYPGHMRGEZCKPT-MOOYVADDSA-N 0.000 description 1
- IRQCYECBTDKFRF-SFHVURJKSA-N COCCO[C@@H](CO)c1cc(F)ccc1OCc1ccccc1 Chemical compound COCCO[C@@H](CO)c1cc(F)ccc1OCc1ccccc1 IRQCYECBTDKFRF-SFHVURJKSA-N 0.000 description 1
- SPOQHLFEVJKFTQ-LBPRGKRZSA-N COc(c([C@H](CO)OCCC#N)c1)ccc1F Chemical compound COc(c([C@H](CO)OCCC#N)c1)ccc1F SPOQHLFEVJKFTQ-LBPRGKRZSA-N 0.000 description 1
- GMLPMEGZMIPECX-CCLHPLFOSA-N C[C@@](CC1)(CNC1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O Chemical compound C[C@@](CC1)(CNC1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O GMLPMEGZMIPECX-CCLHPLFOSA-N 0.000 description 1
- FXTAHZAZWNHKDC-SIBVEZHUSA-N C[C@](CC1)(CNC1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCO)[s]c(-[n]3nccn3)c1C)=O)C2=O Chemical compound C[C@](CC1)(CNC1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCO)[s]c(-[n]3nccn3)c1C)=O)C2=O FXTAHZAZWNHKDC-SIBVEZHUSA-N 0.000 description 1
- IHJNANLZZYSAQH-DEOSSOPVSA-N C[C@](CCCN1)(C1=O)N(C(c1c(N2CCc3cc(F)ccc3OC)[s]c(-[n]3nccn3)c1C)=O)C2=O Chemical compound C[C@](CCCN1)(C1=O)N(C(c1c(N2CCc3cc(F)ccc3OC)[s]c(-[n]3nccn3)c1C)=O)C2=O IHJNANLZZYSAQH-DEOSSOPVSA-N 0.000 description 1
- BRYPDTXWGDTQFO-SIBVEZHUSA-N C[C@](CCN1)(C1=O)N(C(c1c(N2C[C@@H](c(cc(cc3)F)c3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O Chemical compound C[C@](CCN1)(C1=O)N(C(c1c(N2C[C@@H](c(cc(cc3)F)c3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O BRYPDTXWGDTQFO-SIBVEZHUSA-N 0.000 description 1
- KIKTYQZUPCXXJL-DCFHFQCYSA-N C[C@](CCN1C)(C1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O Chemical compound C[C@](CCN1C)(C1=O)N(C(c1c(N2C[C@@H](c3cc(F)ccc3OC)OCCOC)[s]c(-[n]3nccn3)c1C)=O)C2=O KIKTYQZUPCXXJL-DCFHFQCYSA-N 0.000 description 1
- UEINABSOPOXWAD-UHFFFAOYSA-N Cc1c(-[n]2nccc2)[s]c(N(CCc2cc(F)ccc2OC)C(N2C(C3)(C3CN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(N(CCc2cc(F)ccc2OC)C(N2C(C3)(C3CN3C)C3=O)=O)c1C2=O UEINABSOPOXWAD-UHFFFAOYSA-N 0.000 description 1
- VMGQHRGDUYTQEL-QUCCMNQESA-N Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC(O)=O)C(N2[C@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC(O)=O)C(N2[C@H](CCN3C)C3=O)=O)c1C2=O VMGQHRGDUYTQEL-QUCCMNQESA-N 0.000 description 1
- QKFVRRJIOAVDLW-IRLDBZIGSA-N Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC=C)C(N2[C@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccc2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCC=C)C(N2[C@H](CCN3C)C3=O)=O)c1C2=O QKFVRRJIOAVDLW-IRLDBZIGSA-N 0.000 description 1
- RBYAFGLXTNYQSI-IBGZPJMESA-N Cc1c(-[n]2nccn2)[s]c(N(C(c2ccccc2)c2ccccc2)C(N2[C@@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C(c2ccccc2)c2ccccc2)C(N2[C@@H](CCN3)C3=O)=O)c1C2=O RBYAFGLXTNYQSI-IBGZPJMESA-N 0.000 description 1
- RLAYVLXTRPAUDR-HNNXBMFYSA-N Cc1c(-[n]2nccn2)[s]c(N(CC(c(cc(cc2)F)c2OC)=O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CC(c(cc(cc2)F)c2OC)=O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O RLAYVLXTRPAUDR-HNNXBMFYSA-N 0.000 description 1
- PXEXCCHKEYEPAN-HNNXBMFYSA-N Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O PXEXCCHKEYEPAN-HNNXBMFYSA-N 0.000 description 1
- ASAJCDYYBOCJMF-KRWDZBQOSA-N Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2OC)C(N2[C@@H](CCCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2OC)C(N2[C@@H](CCCN3C)C3=O)=O)c1C2=O ASAJCDYYBOCJMF-KRWDZBQOSA-N 0.000 description 1
- HKZPTZCINATFJR-QFIPXVFZSA-N Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2OCc2ccccc2)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(CCc2cc(F)ccc2OCc2ccccc2)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O HKZPTZCINATFJR-QFIPXVFZSA-N 0.000 description 1
- LJACHIDNICEUNB-YANBTOMASA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OC2CCOCC2)C(N2C(CCCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OC2CCOCC2)C(N2C(CCCN3C)C3=O)=O)c1C2=O LJACHIDNICEUNB-YANBTOMASA-N 0.000 description 1
- UNBALTRFYAIKKN-QWAKEFERSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OC2CCOCC2)C(N2C(CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OC2CCOCC2)C(N2C(CCN3)C3=O)=O)c1C2=O UNBALTRFYAIKKN-QWAKEFERSA-N 0.000 description 1
- WQZFTJHGQWZFCY-ICSRJNTNSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OCCC#N)C(N2[C@@H](CCCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cc(cc2)F)c2OC)OCCC#N)C(N2[C@@H](CCCN3)C3=O)=O)c1C2=O WQZFTJHGQWZFCY-ICSRJNTNSA-N 0.000 description 1
- OYIONNYDZCYFLB-HOTGVXAUSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cccc2)c2OC)O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c(cccc2)c2OC)O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O OYIONNYDZCYFLB-HOTGVXAUSA-N 0.000 description 1
- GRNDYNNFMRBNNA-HOTGVXAUSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)O)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O GRNDYNNFMRBNNA-HOTGVXAUSA-N 0.000 description 1
- SIDPXYSZWFUFFQ-WMZOPIPTSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OC)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OC)C(N2[C@@H](CCN3C)C3=O)=O)c1C2=O SIDPXYSZWFUFFQ-WMZOPIPTSA-N 0.000 description 1
- LJACHIDNICEUNB-GGAORHGYSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OC2CCOCC2)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O LJACHIDNICEUNB-GGAORHGYSA-N 0.000 description 1
- SXPZGKCCLAYXJP-YBSONKRPSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCC/C=N\C)C(N2[C@@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCC/C=N\C)C(N2[C@@H](CCN3)C3=O)=O)c1C2=O SXPZGKCCLAYXJP-YBSONKRPSA-N 0.000 description 1
- GPAJRHSFORUDNA-XSFKQQOJSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@H](C3)CNC3O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@H](C3)CNC3O)=O)c1C2=O GPAJRHSFORUDNA-XSFKQQOJSA-N 0.000 description 1
- YKQIABFCCPAZMK-QUCCMNQESA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCO)C(N2[C@H](CCCN3C)C3=O)=O)c1C2=O YKQIABFCCPAZMK-QUCCMNQESA-N 0.000 description 1
- ZAHLWJLQISGEOI-CVMIBEPCSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2C(C3)CNC3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2C(C3)CNC3=O)=O)c1C2=O ZAHLWJLQISGEOI-CVMIBEPCSA-N 0.000 description 1
- OKIWPZXQLCKBCK-NNBQYGFHSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2C(CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2C(CCN3)C3=O)=O)c1C2=O OKIWPZXQLCKBCK-NNBQYGFHSA-N 0.000 description 1
- ODIVQSJHGIEZCJ-SFHVURJKSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2CCO)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OC)OCCOC)C(N2CCO)=O)c1C2=O ODIVQSJHGIEZCJ-SFHVURJKSA-N 0.000 description 1
- ZFOHJDAHSVJFAV-YPTUDWLLSA-N Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OCc2ccccc2)O[C@H](CC2)CC[C@H]2O)C(N2[C@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(N(C[C@@H](c2cc(F)ccc2OCc2ccccc2)O[C@H](CC2)CC[C@H]2O)C(N2[C@H](CCN3)C3=O)=O)c1C2=O ZFOHJDAHSVJFAV-YPTUDWLLSA-N 0.000 description 1
- OKAFSYIUQMCKOT-UHFFFAOYSA-N Cc1c(-[n]2nccn2)[s]c(NC(N2C(C3)CNC3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(NC(N2C(C3)CNC3=O)=O)c1C2=O OKAFSYIUQMCKOT-UHFFFAOYSA-N 0.000 description 1
- CWYDJCNBLIRUDA-UHFFFAOYSA-N Cc1c(-[n]2nccn2)[s]c(NC(N2C(CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(NC(N2C(CCN3)C3=O)=O)c1C2=O CWYDJCNBLIRUDA-UHFFFAOYSA-N 0.000 description 1
- CWYDJCNBLIRUDA-ZETCQYMHSA-N Cc1c(-[n]2nccn2)[s]c(NC(N2[C@@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(NC(N2[C@@H](CCN3)C3=O)=O)c1C2=O CWYDJCNBLIRUDA-ZETCQYMHSA-N 0.000 description 1
- CWYDJCNBLIRUDA-SSDOTTSWSA-N Cc1c(-[n]2nccn2)[s]c(NC(N2[C@H](CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(-[n]2nccn2)[s]c(NC(N2[C@H](CCN3)C3=O)=O)c1C2=O CWYDJCNBLIRUDA-SSDOTTSWSA-N 0.000 description 1
- POAJIKIWDGNSKL-LJUJANAJSA-N Cc1c(N/N=C\C=N)[s]c(NC(N2C(CCN3)C3=O)=O)c1C2=O Chemical compound Cc1c(N/N=C\C=N)[s]c(NC(N2C(CCN3)C3=O)=O)c1C2=O POAJIKIWDGNSKL-LJUJANAJSA-N 0.000 description 1
- JIMSBKAHGYGPLD-UHFFFAOYSA-N NC(C1)CNC1=O Chemical compound NC(C1)CNC1=O JIMSBKAHGYGPLD-UHFFFAOYSA-N 0.000 description 1
- YNDAMDVOGKACTP-UHFFFAOYSA-N NC(CCN1)C1=O Chemical compound NC(CCN1)C1=O YNDAMDVOGKACTP-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N O=C1NCCCC1 Chemical compound O=C1NCCCC1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- QILSFLSDHQAZET-UHFFFAOYSA-N OC(c1ccccc1)c1ccccc1 Chemical compound OC(c1ccccc1)c1ccccc1 QILSFLSDHQAZET-UHFFFAOYSA-N 0.000 description 1
- KBXLRWUMQGXSDV-NRFANRHFSA-N OC[C@@H](c1cc(F)ccc1OCc1ccccc1)OC(CC1)CCC1=O Chemical compound OC[C@@H](c1cc(F)ccc1OCc1ccccc1)OC(CC1)CCC1=O KBXLRWUMQGXSDV-NRFANRHFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pest Control & Pesticides (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246318P | 2015-10-26 | 2015-10-26 | |
US62/246,318 | 2015-10-26 | ||
PCT/US2016/058867 WO2017075056A1 (en) | 2015-10-26 | 2016-10-26 | Acc inhibitors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018538246A true JP2018538246A (ja) | 2018-12-27 |
JP2018538246A5 JP2018538246A5 (he) | 2019-12-05 |
Family
ID=57233943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018521087A Pending JP2018538246A (ja) | 2015-10-26 | 2016-10-26 | Acc阻害剤およびその使用 |
Country Status (14)
Country | Link |
---|---|
US (2) | US10179793B2 (he) |
EP (1) | EP3368540A1 (he) |
JP (1) | JP2018538246A (he) |
KR (1) | KR20180067603A (he) |
CN (1) | CN108368125A (he) |
AR (1) | AR106472A1 (he) |
AU (1) | AU2016344392A1 (he) |
BR (1) | BR112018008227A2 (he) |
CA (1) | CA3003275A1 (he) |
EA (1) | EA201890749A1 (he) |
IL (1) | IL258636A (he) |
MX (1) | MX2018005292A (he) |
SG (1) | SG11201802989QA (he) |
WO (1) | WO2017075056A1 (he) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021112213A1 (ja) * | 2019-12-05 | 2021-06-10 | 日本曹達株式会社 | 2,4-ジオキソ-1,4-ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤 |
JP2022551014A (ja) * | 2019-12-05 | 2022-12-06 | ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 | Acc1及びacc2阻害剤としての結晶形及びその製造方法並びに使用 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2855372C (en) | 2011-11-11 | 2022-03-22 | Nimbus Apollo, Inc. | 2,4-dioxo-thieno[2,3-d]pyrimidinyl derivatives and pharmaceutical compositions thereof used as acc inhibitors |
US10301292B2 (en) | 2014-11-26 | 2019-05-28 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
CN108349995B (zh) | 2015-11-25 | 2021-08-03 | 吉利德阿波罗公司 | 吡唑acc抑制剂及其用途 |
PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
WO2017091602A1 (en) | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Ester acc inhibitors and uses thereof |
EA201890910A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА |
TWI818828B (zh) * | 2016-03-02 | 2023-10-11 | 美商基利阿波羅有限責任公司 | 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法 |
KR20190053242A (ko) | 2016-09-23 | 2019-05-17 | 바이엘 악티엔게젤샤프트 | N3-시클릭 치환된 티에노우라실 및 그의 용도 |
EP3571205B1 (en) | 2017-01-22 | 2023-08-30 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
CN110382504A (zh) * | 2017-03-03 | 2019-10-25 | 吉利德阿波罗公司 | 制备杀真菌化合物的方法 |
EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
CN110709402B (zh) * | 2017-06-15 | 2022-05-10 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 |
TW201910338A (zh) | 2017-07-26 | 2019-03-16 | 大陸商南京聖和藥業股份有限公司 | 作為acc抑制劑的化合物及其應用 |
WO2019191451A1 (en) | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
US11680070B2 (en) | 2018-06-05 | 2023-06-20 | Medshine Discovery Inc. | Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof |
EA202191224A1 (ru) * | 2018-11-02 | 2021-07-29 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Композиции, содержащие галауксифен и другие гербициды, и связанные с ними способы |
WO2020103851A1 (zh) * | 2018-11-20 | 2020-05-28 | 中国医药研究开发中心有限公司 | 螺环类化合物及其医药用途 |
CN111484504B (zh) * | 2019-01-25 | 2024-05-10 | 南京圣和药业股份有限公司 | Acc抑制剂的光学异构体及其应用 |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
CN110746439B (zh) * | 2019-10-18 | 2020-10-30 | 南京瑞捷医药科技有限公司 | 一种噻吩并嘧啶二酮化合物的制备方法 |
WO2021110138A1 (zh) * | 2019-12-05 | 2021-06-10 | 漳州片仔癀药业股份有限公司 | 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN113968871A (zh) * | 2020-07-25 | 2022-01-25 | 南京圣和药业股份有限公司 | 苯基取代类acc抑制剂的晶型 |
WO2022133097A1 (en) * | 2020-12-17 | 2022-06-23 | Biogen Ma Inc. | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels |
CN116583286A (zh) | 2020-12-24 | 2023-08-11 | 某久拉斯株式会社 | 四氢噻吩并嘧啶磺酰胺化合物 |
WO2022268520A1 (de) * | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
CN115677551A (zh) * | 2021-12-28 | 2023-02-03 | 武汉市振邦生物科技有限公司 | 一种2-氧代吡咯烷-3-甲酸乙酯的制备工艺 |
CN115433756B (zh) * | 2022-08-30 | 2024-04-09 | 山东新华制药股份有限公司 | 一种泼尼松龙的制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62289583A (ja) * | 1986-04-28 | 1987-12-16 | オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン | チエノピリミジン−2,4−ジオン誘導体類およびそれらの中間生成物類 |
US4835157A (en) * | 1988-03-15 | 1989-05-30 | Ortho Pharmaceutical Corporation | Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents |
JPH0761986A (ja) * | 1990-02-22 | 1995-03-07 | Takeda Chem Ind Ltd | 縮合チオフェン誘導体 |
US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
JP2003292492A (ja) * | 2002-01-30 | 2003-10-15 | Takeda Chem Ind Ltd | チエノピリミジン化合物、その製造法および用途 |
JP2004518732A (ja) * | 2001-02-14 | 2004-06-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’2,3−dピリミジンジオン誘導体 |
WO2008143262A1 (ja) * | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
JP2014533281A (ja) * | 2011-11-11 | 2014-12-11 | ニンバス アポロ, インコーポレイテッド | Acc阻害剤およびその使用 |
WO2015007451A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02225485A (ja) | 1989-02-27 | 1990-09-07 | Taiho Yakuhin Kogyo Kk | チエノピリミジン―3―酢酸誘導体 |
JP3811196B2 (ja) | 1993-08-26 | 2006-08-16 | 武田薬品工業株式会社 | エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法 |
TW276256B (he) | 1993-08-26 | 1996-05-21 | Takeda Pharm Industry Co Ltd | |
DE69624829T2 (de) | 1995-08-17 | 2003-07-31 | Takeda Chemical Industries Ltd | Thienopyrimidinderivate als endothelin antagonisten |
JPH09110873A (ja) | 1995-08-17 | 1997-04-28 | Takeda Chem Ind Ltd | チエノピリミジン誘導体、その製造法および用途 |
AU2407997A (en) | 1996-04-30 | 1997-11-19 | Takeda Chemical Industries Ltd. | Combined use of gnrh agonist and antagonist |
JP2007302703A (ja) | 1996-04-30 | 2007-11-22 | Takeda Chem Ind Ltd | 医薬組成物 |
US6984644B2 (en) | 1997-05-28 | 2006-01-10 | Astrazeneca Ab | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones |
SE9702001D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
DE19754082A1 (de) | 1997-12-05 | 1999-06-10 | Knoll Ag | Methode zur Bekämpfung der Fettleibigkeit |
ATE312102T1 (de) | 1999-04-09 | 2005-12-15 | Cell Therapeutics Inc | Xanthinderivate und analoge als zellsignalisierung inhibitoren |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
EP1585392B1 (en) | 2003-01-06 | 2009-03-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Herbicides inhibiting the action of plant acetyl-coa carboxylase for use as pesticides. |
CN100360538C (zh) | 2003-01-29 | 2008-01-09 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
WO2006014647A2 (en) | 2004-07-21 | 2006-02-09 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
WO2007103776A2 (en) | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
US9365584B2 (en) | 2009-12-29 | 2016-06-14 | Poxel | Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof |
CA2799416A1 (en) | 2010-05-14 | 2011-11-17 | University Of Rochester | Compositions and methods for targeting a3g:rna complexes |
CN105358152A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
CA2911932A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
WO2014182951A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
WO2014182950A1 (en) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
TWI652012B (zh) | 2013-05-20 | 2019-03-01 | 杜邦股份有限公司 | 殺真菌吡唑的固態形式 |
WO2015007453A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
CN108349995B (zh) | 2015-11-25 | 2021-08-03 | 吉利德阿波罗公司 | 吡唑acc抑制剂及其用途 |
EA201890910A1 (ru) | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | ФУНГИЦИДНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 2,4-ДИОКСО-1,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИНА |
PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
WO2017091602A1 (en) | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Ester acc inhibitors and uses thereof |
TWI818828B (zh) | 2016-03-02 | 2023-10-11 | 美商基利阿波羅有限責任公司 | 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法 |
-
2016
- 2016-10-25 AR ARP160103255A patent/AR106472A1/es unknown
- 2016-10-26 EP EP16791253.4A patent/EP3368540A1/en not_active Withdrawn
- 2016-10-26 WO PCT/US2016/058867 patent/WO2017075056A1/en active Application Filing
- 2016-10-26 MX MX2018005292A patent/MX2018005292A/es unknown
- 2016-10-26 JP JP2018521087A patent/JP2018538246A/ja active Pending
- 2016-10-26 US US15/334,955 patent/US10179793B2/en not_active Expired - Fee Related
- 2016-10-26 CN CN201680072737.1A patent/CN108368125A/zh active Pending
- 2016-10-26 KR KR1020187013132A patent/KR20180067603A/ko unknown
- 2016-10-26 BR BR112018008227A patent/BR112018008227A2/pt not_active Application Discontinuation
- 2016-10-26 CA CA3003275A patent/CA3003275A1/en not_active Abandoned
- 2016-10-26 AU AU2016344392A patent/AU2016344392A1/en not_active Abandoned
- 2016-10-26 SG SG11201802989QA patent/SG11201802989QA/en unknown
- 2016-10-26 EA EA201890749A patent/EA201890749A1/ru unknown
-
2018
- 2018-04-11 IL IL258636A patent/IL258636A/he unknown
- 2018-11-27 US US16/201,571 patent/US20190330224A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62289583A (ja) * | 1986-04-28 | 1987-12-16 | オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン | チエノピリミジン−2,4−ジオン誘導体類およびそれらの中間生成物類 |
US4835157A (en) * | 1988-03-15 | 1989-05-30 | Ortho Pharmaceutical Corporation | Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents |
JPH0761986A (ja) * | 1990-02-22 | 1995-03-07 | Takeda Chem Ind Ltd | 縮合チオフェン誘導体 |
US6166019A (en) * | 1998-07-16 | 2000-12-26 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
JP2004518732A (ja) * | 2001-02-14 | 2004-06-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’2,3−dピリミジンジオン誘導体 |
JP2003292492A (ja) * | 2002-01-30 | 2003-10-15 | Takeda Chem Ind Ltd | チエノピリミジン化合物、その製造法および用途 |
WO2008143262A1 (ja) * | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
JP2014533281A (ja) * | 2011-11-11 | 2014-12-11 | ニンバス アポロ, インコーポレイテッド | Acc阻害剤およびその使用 |
WO2015007451A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021112213A1 (ja) * | 2019-12-05 | 2021-06-10 | 日本曹達株式会社 | 2,4-ジオキソ-1,4-ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤 |
JP2022551014A (ja) * | 2019-12-05 | 2022-12-06 | ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 | Acc1及びacc2阻害剤としての結晶形及びその製造方法並びに使用 |
JP7265681B2 (ja) | 2019-12-05 | 2023-04-26 | ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 | Acc1及びacc2阻害剤としての結晶形及びその製造方法並びに使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2016344392A1 (en) | 2018-05-10 |
US20190330224A1 (en) | 2019-10-31 |
WO2017075056A1 (en) | 2017-05-04 |
CN108368125A (zh) | 2018-08-03 |
EA201890749A1 (ru) | 2018-11-30 |
CA3003275A1 (en) | 2017-05-04 |
US20170145028A1 (en) | 2017-05-25 |
SG11201802989QA (en) | 2018-05-30 |
MX2018005292A (es) | 2018-08-01 |
AR106472A1 (es) | 2018-01-17 |
IL258636A (he) | 2018-06-28 |
EP3368540A1 (en) | 2018-09-05 |
US10179793B2 (en) | 2019-01-15 |
KR20180067603A (ko) | 2018-06-20 |
BR112018008227A2 (pt) | 2018-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10179793B2 (en) | ACC inhibitors and uses thereof | |
US10800791B2 (en) | Triazole ACC inhibitors and uses thereof | |
US10941158B2 (en) | Pyrazole ACC inhibitors and uses thereof | |
US10472374B2 (en) | ACC inhibitors and uses thereof | |
US11098055B2 (en) | Ester ACC inhibitors and uses thereof | |
TW201400489A (zh) | Acc抑制劑及彼等之用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191024 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191024 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200929 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201002 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210506 |